Keyphrases
Bleeding
100%
Vitamin K Antagonists
100%
Bleeding Patients
100%
Prothrombin Complex Concentrate
100%
Antagonist Treatment
100%
Risk of Bias
45%
Fresh Frozen Plasma
45%
Confidence Interval
36%
Randomized Controlled Trial
36%
Risk Ratio
36%
Transfusion
36%
MEDLINE
18%
Overall Mortality
18%
Coagulopathy
18%
Clinical Analysis
18%
Vitamin K
18%
Search Strategy
18%
Review Authors
18%
Ovid
18%
Clinical Outcomes
9%
High Risk
9%
Low Risk
9%
Adverse Events
9%
Embase
9%
Meta-analysis
9%
Beneficial Effects
9%
Primary Outcome Measure
9%
Randomized Clinical Trial
9%
Clinically Significant
9%
Mortality Risk
9%
Intervention Effect
9%
Surgical Patients
9%
Subgroup Analysis
9%
Sensitivity Analysis
9%
Cochrane Central Register of Controlled Trials
9%
Web of Science
9%
Statistical Interaction
9%
Surgical Environment
9%
Red Blood Cells
9%
Transfusion Requirements
9%
Surgical Intervention
9%
Health Sciences
9%
Bleeding Complications
9%
Random Error
9%
Nursing
9%
Statistical Heterogeneity
9%
Literature Database
9%
Long Follow-up
9%
Clinical Heterogeneity
9%
Ongoing Trials
9%
Mortality Benefit
9%
High-quality Research
9%
28-day Mortality
9%
Continuous Outcomes
9%
Dichotomous Outcomes
9%
Cumulative Index
9%
Allied Health
9%
Health Literature
9%
Review Update
9%
Publication Status
9%
Google
9%
Observational Evidence
9%
Biomedical Literature
9%
High Risk of Bleeding
9%
Medical Setting
9%
Caribbean
9%
Latin American
9%
Formal Review
9%
Science Literature
9%
New Occurrence
9%
Reversal Therapy
9%
Physiological Outcomes
9%
Medicine and Dentistry
Bleeding
100%
Vitamin K Antagonist
100%
Prothrombin Complex
100%
Fresh Frozen Plasma
45%
Randomized Controlled Trial
36%
Coagulopathy
18%
Sequential Analysis
18%
Adverse Event
9%
Meta-Analysis
9%
Systematic Review
9%
Surgery
9%
Randomized Clinical Trial
9%
Subgroup Analysis
9%
Erythrocyte
9%
Pharmacology, Toxicology and Pharmaceutical Science
Bleeding
100%
Antivitamin K
100%
Prothrombin Complex
100%
Fresh Frozen Plasma
45%
Randomized Controlled Trial
36%
Blood Clotting Disorder
18%
Vitamin K Group
18%
Adverse Event
9%
Randomized Clinical Trial
9%